PerpEquities

Equity · Healthcare

Pfizer Inc. (PFE) perpetual futures

PFE perpetual futures on 15 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PFEUSDT.

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines for diverse therapeutic areas, including COVID-19 treatments like Paxlovid and vaccines like Comirnaty.

$27.49-0.1%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · Ourbit (PFE/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

15/15 live markets
Venues
15
Live markets
15/15
24h volume
$3.6M
Open interest
$679.8KCoverage: 12/15 markets
Best liquidity
$444.5K
Bitget
Tightest spread
+0.4 bps
Bitget
Highest volume
$1.8M
Ourbit
Settlement mix
USDT · 13/15
Perp/spot vol.
0.00x
Spot volume $1.1B
OI / float
0.00%
Float $156.6B
Spot performance
1D-0.51%
5D-6.26%
1M-9.93%
6M+5.79%
YTD+10.04%
1Y+8.64%

Venue matrix

15 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
OurbitTradePFE/USDTTrading$27.470.0% APR
0.000% every 8h
+7.3 bps$160.5K$1.8M$187.5KUSDT20x
XT.comTradePFE/USDTTrading$27.480.0% APR
0.000% every 8h
+7.3 bps$31.6K$263K-USDT20x
KuCoinTradePFE/USDTTrading$27.490.0% APR
0.000% every 8h
+30.2 bps$3.7K$241.5K$5.3KUSDT20x
BinanceTradePFE/USDTTrading$27.480.0% APR
0.000% every 8h
+7.3 bps$52.8K$175.3K$115.9KUSDT-
BingXTradePFE-USDTTrading$27.61-5.5% APR
-0.00500% every 8h
+10.9 bps$53.8K$144.8K$758.4USDT-
VariationalTradePFE/USDCTrading$27.430.0% APR
0.000% every 8h
+14.3 bpsno public depth feed$127.5K$5.1KUSDC-
MEXCTradePFE/USDTTrading$27.470.0% APR
0.000% every 8h
+7.3 bps$55.4K14 min$101.6K$21.6KUSDT20x
BitunixTradePFE/USDTTrading$27.48-1.9% APR
-0.00177% every 8h
+14.6 bps$49.1K$74.1K$20.8KUSDT20x
HTXTradePFE/USDTTrading$27.480.0% APR
0.000% every 8h
+97.7 bps$7K$30.4K$6KUSDT-
BitgetTradePFE/USDTTrading$27.490.0% APR
0.000% every 8h
+0.4 bps$444.5K$20.9K$159.8KUSDT20x
OKXTradePFE/USDTTrading$27.520.0% APR
0.000% every 8h
+12.7 bps$8.5K$5.3K$64KUSDT20x
BybitTradePFE/USDTTrading$27.420.0% APR
0.000% every 8h
+18.2 bps$8.7K$437.6$63.7KUSDT25x
Helix (Injective)TradePFE/USDCTrading$27.44-24.1% APR
-0.00275% every 1h
-$0$343.5-USDC12x
Gate.ioTradePFE/USDTTrading$27.480.0% APR
0.000% every 8h
+40.0 bps$22.1K$49$29.4KUSDT20x
LBankTradePFE/USDTTrading$27.480.0% APR
0.000% every 8h
+7.3 bps$368.4K$618.6K-USDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Broad liquidity · 10 of 15 venues absorb $10k · Typical cost: +21.8 bps – +44.6 bps

Too thin: OKX, HTX, KuCoin

No fresh book data: Variational, Helix (Injective)

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

PFE

Tightest spread

PFE

Highest volume

PFE

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-03 · next report 2027-02-02 · Updated 3h ago
All financials →

Valuation & key figures

Market cap
$156B
Updated 3h ago
Revenue
$63.6B
Trailing 12 months
Revenue growth
+1%
FY2026 consensus
Profit margin
6.3%
Net income / revenue, TTM
P/E
39.5×
Forward 9.0× (FY2026)
P/S
2.5×
Price / sales, TTM
Peer P/E
30.1×
Similar listed perps
EV / EBITDA
16.1×
TTM
Free cash flow
$11.8B
Trailing 12 months
Net income
$4.03B
Trailing 12 months
Revenue estimate
$63.2B
FY2026 consensus
Earnings
2027-02-02
Revenue est. $17.2B · Updated 3h ago
Dividend
$0.43
Per payment · 2026-11-06
Revenue (TTM)$63.6B+1.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)23.8%-3.1 pp vs a year agoOperating income $15.2B
Net income (TTM)$4.03B-59.0% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$11.8B+13.6% vs a year agoCapex $2.39B
Diluted EPS (TTM)$0.70-59.5% vs a year agoSum of the last 4 quarters
Net cash-$48.4B-3.6% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-03): revenue beat by 4.6%, EPS beat by 18.4%Revenue $16.6B vs $15.9B expected (+4.6%); EPS $0.87 vs $0.74 (+18.4%).
  • Revenue growth steady: -0.4% year on yearQ3 '26 revenue $16.6B, against an average of 0.2% over the four quarters before.
  • Operating margin 23.8% (TTM), -3.1 pp on a year agoOperating income grew -10.3% while revenue grew 1.3%.
  • 256.0% of pre-tax profit is eaten by non-operating lossesPre-tax income $4.26B vs operating income $15.2B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

Q3 '26
LineRevenuey/yShare of listed
Biopharma Segment$16.3B-0.2%98.2%
Segment Reporting, Reconciling Item, Corporate Nonsegment$300M-12.8%1.8%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 337 lines Pfizer Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-02
Revenue est. $17.2B · Updated 3h ago
Dividend
$0.43
2026-11-06

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20263.05$63.2B+1%13
FY 20272.96$60.7B-4%14
FY 20282.46$55.2B-9%7
FY 20292.25$53.7B-3%2
FY 20302.31$54.3B+1%4
Q3 20260.74$15.9B-4%12
Source: FMP · Consensus

Company events

6
2027-02-02EarningsActual - / Estimate 0.69-
2026-11-06Dividend$0.43-
2026-11-03Earnings · Before market openActual 0.87 / Estimate 0.735Beat
2026-08-04EarningsActual 0.77 / Estimate 0.682Beat
2026-07-24Dividend$0.43-
2026-05-08Dividend$0.43-

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 08:31 AM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Albert Bourla
Employees
75,000
IPO date
Jun 1, 1972
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei2.1
Piotroski scorei7/9
Overall ratingiB
Owner earningsi$4.78B$0.83 per share
ESG risk ratingiB+Industry rank: 11/28

Rating factors

Return on equityi
3/5
Return on assetsi
4/5
Debt to equityi
1/5
Price to earningsi
1/5
Price to booki
3/5
Market cap history
$156.18B-2.4%Aug 2026 – Nov 2026
$156.18B$165.50B$174.82BHigh: $174.82B · 2026-11-02Latest: $156.18B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $156.18B · 2026-11-20High: $174.82B · 2026-11-02Low: $156.18B · 2026-11-20
Largest fund holders
FundWeightShares held
VOO0.27%151.5M
VTS.AX0.24%142.8M
VTI0.24%142.8M
1655.T0.25%76.6M
1657.T0.19%76.6M
XAW.TO0.15%76.6M
IVV0.25%76.5M
FXAIX0.25%73.1M
SPY0.25%69.9M
VTV0.63%54.8M
XLV2.4%42.1M
VIIIX0.27%30M

Analyst track record

How the analysts covering PFE have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings205582
Analysts3141
Buy / hold / sell64 / 130 / 11181 / 388 / 13
Upgrades / downgrades / initiations4 / 3 / 36 / 7 / 9
Price targets hit / missed72 / 114 (39%)125 / 389 (24%)
Avg. return after a rating (TipRanks)-3.8%-7.4%
Best / worst call+10.2% / -23.5%+19.7% / -76.1%

After buy calls on this stock: median 21-day move -0.2% vs S&P 500 -1.8% (n = 187)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Evan SeigermanBMO Capital8% hit rate on this stock · 25 targets measuredBuytarget $35.00Nov 4, 2026
  2. Louise ChenScotiabank7% hit rate on this stock · 14 targets measuredBuytarget $35.00Nov 4, 2026
  3. Akash TewariJefferies0% hit rate on this stock · 28 targets measuredBuytarget $36.00Nov 3, 2026

Latest ratings

DateAnalystCallTarget
Nov 16, 2026Emily FieldBarclaysNov 16, 2026SellMaintained$25.00↗
Nov 16, 2026Unknown AnalystLeerink PartnersNov 16, 2026HoldMaintained–
Nov 6, 2026Ilya ZubkovFreedom Capital MarketsNov 6, 2026BuyMaintained$34.00↗
Nov 5, 2026Elmar KrausDZ BANK AGNov 5, 2026HoldDowngraded–↗
Nov 4, 2026Vamil DivanGuggenheimNov 4, 2026BuyMaintained$33.00↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$24.00$25.00$26.00$27.00$28.00$29.00$30.00$31.00Dec 25 · Buy 6 · Hold 14 · Sell 1Dec 25Jan 26 · Buy 6 · Hold 15 · Sell 1Feb 26 · Buy 8 · Hold 14 · Sell 3Feb 26Mar 26 · Buy 8 · Hold 14 · Sell 2Apr 26 · Buy 8 · Hold 14 · Sell 2Apr 26May 26 · Buy 9 · Hold 14 · Sell 3Jun 26 · Buy 9 · Hold 14 · Sell 2Jun 26Jul 26 · Buy 8 · Hold 15 · Sell 2Aug 26 · Buy 8 · Hold 14 · Sell 2Aug 26Sep 26 · Buy 8 · Hold 14 · Sell 2Oct 26 · Buy 8 · Hold 17 · Sell 2Oct 26Nov 26 · Buy 8 · Hold 17 · Sell 1Dec 25 · avg. target $28.37Jan 26 · avg. target $28.25Feb 26 · avg. target $28.64Mar 26 · avg. target $28.98Apr 26 · avg. target $29.02May 26 · avg. target $29.11Jun 26 · avg. target $29.26Jul 26 · avg. target $28.75Aug 26 · avg. target $28.32Sep 26 · avg. target $28.43Oct 26 · avg. target $29.17Nov 26 · avg. target $30.18Dec 25 · month-end close $24.90Jan 26 · month-end close $26.44Feb 26 · month-end close $27.65Mar 26 · month-end close $28.08Apr 26 · month-end close $26.70May 26 · month-end close $26.18Jun 26 · month-end close $24.08Jul 26 · month-end close $25.01Aug 26 · month-end close $28.46Sep 26 · month-end close $28.52Oct 26 · month-end close $30.52Nov 26 · month-end close $27.40

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 205 ratings

Frequently asked questions

Where can I trade PFE perpetual futures?

Pfizer Inc. (PFE) perpetual futures trade on 15 crypto venues, including Ourbit, LBank, XT.com. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade PFE around the clock?

Yes. Unlike the underlying stock, PFE perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on PFE perpetuals?

Right now the PFE perp funding rate is 0.0% annualized (venue median), ranging from -24.1% to 0.0% across 15 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the PFE perp price compare to the Pfizer Inc. stock?

The venue-median PFE perp mark is $27.5 versus a reference stock price of $27.5, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a PFE perpetual future?

A PFE perpetual is a derivative that tracks the price of Pfizer Inc. with no expiry date. It lets you take long or short exposure to Pfizer Inc. on crypto venues, around the clock.

What is PFEUSDT perpetual?

PFEUSDT is the symbol most crypto exchanges use for the Pfizer Inc. perpetual settled in USDT (Tether). It tracks the PFE share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

PFE perpetuals · perpequities.comPFE perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/pfe-perp"><img src="https://perpequities.com/badge/pfe-perp.svg" width="240" height="64" alt="PFE perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of PFE perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for PFE — one email every Sunday.

Watchlist and alerts

Price and funding alerts for PFE, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X